Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-04856884
CVX-060 · 1 trial · 5 indications
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 30 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to CVX-060 was assessed by the investigator (Yes/No). Participants with multiple occurrences of an AE within a category were counted once within the category.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CVX-060 | BIOLOGICAL | Weekly, intravenous dose |
Inclusion Criteria: * Confirmed advanced solid tumors unresponsive to currently available therapies or for which there is no standard therapy. * Adequate coagulation, liver, and renal function. * Candidate for DCE-MRI evaluations. * ECOG (Eastern Cooperative Oncology Group) performance status of 0 ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
CVX-060 is an investigational monoclonal antibody being studied for the treatment of advanced solid tumors, including neoplasms, carcinoma, cancer, and malignancy. It was evaluated in adult patients with advanced solid tumors in a single Phase 1 study. It is not an approved therapy and remains in clinical development.
CVX-060 targets ANGPT2, also known as angiopoietin-2, and acts as an inhibitor of that target. By binding ANGPT2, the monoclonal antibody is designed to interfere with its activity. ANGPT2 is a protein involved in vascular biology, and the compound was studied in advanced solid tumors.
CVX-060 is being developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the Phase 1 study of CVX-060 in patients with advanced solid tumors. The asset is an oncology monoclonal antibody directed at ANGPT2.
CVX-060 is in Phase 1 development. Its only recorded clinical trial, NCT00879684, was a Phase 1 study that has been completed. The drug is investigational and has not been approved for any indication. No active trials of CVX-060 are currently listed.
CVX-060 was studied in one clinical trial, NCT00879684, titled Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors. The Phase 1 trial enrolled 34 patients in the United States, included adults 18 years and older of all sexes, and has been completed. It was an uncontrolled study.